529 related articles for article (PubMed ID: 22281991)
21. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Borgna-Pignatti C; Rugolotto S; De Stefano P; Zhao H; Cappellini MD; Del Vecchio GC; Romeo MA; Forni GL; Gamberini MR; Ghilardi R; Piga A; Cnaan A
Haematologica; 2004 Oct; 89(10):1187-93. PubMed ID: 15477202
[TBL] [Abstract][Full Text] [Related]
22. Coenzyme Q10 levels in β-thalassemia and its association with ferritin levels and chelation therapy.
Karakukcu C; Karakukcu M; Unal E; Patiroglu T; Ozdemir MA; Torun YA; Tang PH
Hemoglobin; 2012; 36(3):219-29. PubMed ID: 22483337
[TBL] [Abstract][Full Text] [Related]
23. [The mechanism of cataract formation in persons with beta-thalassemia].
Popescu C; Siganos D; Zanakis E; Padakis A
Oftalmologia; 1998; 45(4):10-3. PubMed ID: 10418622
[TBL] [Abstract][Full Text] [Related]
24. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia.
Musallam KM; Motta I; Salvatori M; Fraquelli M; Marcon A; Taher AT; Cappellini MD
Blood Cells Mol Dis; 2012 Oct 15-Dec 15; 49(3-4):136-9. PubMed ID: 22727143
[TBL] [Abstract][Full Text] [Related]
25. Thyroid function in thalassaemia major.
Senanayake MP; Suraweera SA; Hubert HD
Ceylon Med J; 1999 Dec; 44(4):166-8. PubMed ID: 10895267
[TBL] [Abstract][Full Text] [Related]
26. [Beta-thalassemia in Germany. Results of cooperative beta-thalassemia study].
Cario H; Stahnke K; Kohne E
Klin Padiatr; 1999; 211(6):431-7. PubMed ID: 10592921
[TBL] [Abstract][Full Text] [Related]
27. Complications of β-thalassemia intermedia in Iran during 1996-2010 (single-center study).
Rafsanjani KA; Mafi N; Tafreshi RI
Pediatr Hematol Oncol; 2011 Sep; 28(6):497-508. PubMed ID: 21728720
[TBL] [Abstract][Full Text] [Related]
28. Effect of splenectomy on iron balance in patients with β-thalassemia major: a long-term follow-up.
Casale M; Cinque P; Ricchi P; Costantini S; Spasiano A; Prossomariti L; Minelli S; Frega V; Filosa A
Eur J Haematol; 2013 Jul; 91(1):69-73. PubMed ID: 23581970
[TBL] [Abstract][Full Text] [Related]
29. Iron overload is associated with low anti-müllerian hormone in women with transfusion-dependent β-thalassaemia.
Chang HH; Chen MJ; Lu MY; Chern JP; Lu CY; Yang YL; Jou ST; Lin DT; Yang YS; Lin KH
BJOG; 2011 Jun; 118(7):825-31. PubMed ID: 21401854
[TBL] [Abstract][Full Text] [Related]
30. Endocrinopathies in beta-thalassemia major. Prevalence, risk factors, and age at diagnosis in Northwest Saudi Arabia.
Habeb AM; Al-Hawsawi ZM; Morsy MM; Al-Harbi AM; Osilan AS; Al-Magamsi MS; Zolaly MA
Saudi Med J; 2013 Jan; 34(1):67-73. PubMed ID: 23299162
[TBL] [Abstract][Full Text] [Related]
31. Endocrine function and bone disease during long-term chelation therapy with deferasirox in patients with β-thalassemia major.
Casale M; Citarella S; Filosa A; De Michele E; Palmieri F; Ragozzino A; Amendola G; Pugliese U; Tartaglione I; Della Rocca F; Cinque P; Nobili B; Perrotta S
Am J Hematol; 2014 Dec; 89(12):1102-6. PubMed ID: 25197009
[TBL] [Abstract][Full Text] [Related]
32. Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major.
Telfer PT; Prestcott E; Holden S; Walker M; Hoffbrand AV; Wonke B
Br J Haematol; 2000 Sep; 110(4):971-7. PubMed ID: 11054091
[TBL] [Abstract][Full Text] [Related]
33. Detection of endocrine disorders in young children with multi-transfused thalassemia major.
Mahmoud RA; Khodeary A; Farhan MS
Ital J Pediatr; 2021 Jul; 47(1):165. PubMed ID: 34332621
[TBL] [Abstract][Full Text] [Related]
34. Endocrinopathies in adolescents with thalassaemia major receiving oral iron chelation therapy.
Sharma R; Seth A; Chandra J; Gohain S; Kapoor S; Singh P; Pemde H
Paediatr Int Child Health; 2016 Feb; 36(1):22-7. PubMed ID: 25311879
[TBL] [Abstract][Full Text] [Related]
35. Elevated serum parathormone levels are associated with myocardial iron overload in patients with beta-thalassaemia major.
Dimitriadou M; Christoforidis A; Economou M; Tsatra I; Vlachaki E; Fidani L; Katzos G; Athanassiou-Metaxa M
Eur J Haematol; 2010 Jan; 84(1):64-71. PubMed ID: 19744128
[TBL] [Abstract][Full Text] [Related]
36. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.
Inati A; Musallam KM; Wood JC; Sheikh-Taha M; Daou L; Taher AT
Eur J Haematol; 2009 Dec; 83(6):565-71. PubMed ID: 19737308
[TBL] [Abstract][Full Text] [Related]
37. High transfusion in children with beta-thalassemia/Hb E: clinical and laboratory assessment of 18 cases.
Torcharus K; Withayathawornwong W; Sriphaisal T; Krutvacho T; Arnutti P; Suwanasophorn C
Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 1():96-9. PubMed ID: 7886617
[TBL] [Abstract][Full Text] [Related]
38. Serum ferritin levels and irregular use of iron chelators predict liver iron load in patients with major beta thalassemia: a cross-sectional study.
Sobhani S; Rahmani F; Rahmani M; Askari M; Kompani F
Croat Med J; 2019 Oct; 60(5):405-413. PubMed ID: 31686454
[TBL] [Abstract][Full Text] [Related]
39. Peroxidative stress and antioxidant enzymes in children with beta-thalassemia major.
Naithani R; Chandra J; Bhattacharjee J; Verma P; Narayan S
Pediatr Blood Cancer; 2006 Jun; 46(7):780-5. PubMed ID: 16317757
[TBL] [Abstract][Full Text] [Related]
40. Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.
Farmaki K; Tzoumari I; Pappa C
Blood Cells Mol Dis; 2011 Jun; 47(1):33-40. PubMed ID: 21531154
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
